'Obvious buying opportunity': Top broker says beaten-up ASX All Ords stock has 253% upside

Wilsons analysts say the market has misread top-line medical trial results released this week.

| More on:
Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX All Ords healthcare stock Immutep Ltd (ASX: IMM) is down by 26% over the past two days, and one market analyst reckons it's a golden buy-the-dip opportunity staring us right in the face.

Immutep shares are currently trading for 32 cents, down 5.97% on Friday. The stock plummeted 47% to an intraday 52-week low of 23 cents yesterday after the company released topline medical trial results.

Let's investigate.

Is this ASX All Ords healthcare stock a buy?

The TACTI-003 Phase IIb Trial is investigating the use of a combination therapy as a first-line treatment for head and neck cancer in 171 patients.

The combined therapy involves Immutep's MHC Class II agonist, eftilagimod alfa (efti), and anti-PD-1 therapy Keytruda (pembrolizumab).

Keytruda is a trademarked drug owned by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co Inc.

In the first cohort of patients, the combined therapy led to a higher overall response rate compared to Keytruda therapy alone.

Results from the second cohort will follow next month, but management said they show an even higher overall response rate.

Sounds positive, so why did investors rush to sell the ASX All Ords healthcare stock?

As my colleague James explained in his coverage yesterday, the selling may have been driven by the absence of a p-value in the results.

The p-value is defined as the probability that the observed effect within the trial would have occurred by chance if there was no true effect.

Immutep has included p-values in study results in the past. So, investors may have wondered about their absence in the announcement.

What do the brokers say?

Wilsons reckons investors have made an error in judgement and punished the ASX All Ords stock unreasonably.

As reported in The Australian, Wilsons said:

The market has yet again misread Immutep and (this) should represent an obvious buying opportunity.

The broker added:

The market is also completely ignoring that Immutep have announced that data from Part B has substantially improved from early data release in April which already demonstrated more than five times vs. Keytruda monotherapy in this cohort.

Wilsons has an overweight rating on Immutep and a share price target of $1.13. This implies a potential 253% upside for this ASX All Ords healthcare stock over the next 12 months.

Bell Potter maintained its speculative buy rating on Immutep after the results were released.

The broker described the results as "a pleasing set of data and certainly supportive of further investment in clinical trials''.

Bell Potter reckons the ASX All Ords stock is worth 80 cents. So, it sees today's price level as a steal.

Immutep share price snapshot

The Immutep share price has risen 13.2% over the past 12 months.

This compares to an 8.85% gain for the S&P/ASX All Ords Index (ASX: XAO).

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Merck. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »